Streetbeat News

Earnings

STX

Structure Therapeutics Inc. has reported an EPS of $(0.20), a significant improvement from $(1.64) YoY.

Portfolio Pulse from Happy Mohamed

August 10, 2023 | 9:08 pm

PROK

ProKidney (NASDAQ:PROK) reported Q2 losses of $(0.12) per share, a 33.33% increase in losses from $(0.09) per share in the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:08 pm

JYNT

Joint Corp reported its Q2 system-wide sales at $120.1 million, marking a 13% increase.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:07 pm

AACG

ATA Creativity Glb (NASDAQ:AACG) reported Q2 losses of $(0.08) per share, beating the analyst consensus estimate of $(0.21) by 61.9%. This is a 20% increase over losses from the same period last year. The company reported $5.00 million in sales, a 1.67% decrease from $5.08 million the same period last year.

Portfolio Pulse from mahesh@benzinga.com

August 10, 2023 | 9:07 pm

ATAI

CMPS

Atai Life Sciences (NASDAQ:ATAI) reported Q2 2023 financial results, with cash and short-term investments of $227.5 million and a net loss attributable to shareholders of $33.1 million. The company's pipeline is advancing 8 programs, six of which are psychedelic-based substances. The Phase 1 trial of oral ibogaine DMX-1002 for Opioid Use Disorder has delivered new clinical results. Other program updates include RL-007, VLS-01, PCN-101, EMP-01, and COMPASS Pathways' COMP360. The company expects its current cash position to fund operations into the first half of 2026.

Portfolio Pulse from Lara Goldstein

August 10, 2023 | 9:06 pm

XELB

Xcel Brands reported Q2 losses of $(0.09) per share, beating the analyst consensus estimate of $(0.13) by 30.77%. This is a 50% increase over losses from the same period last year. The company also reported quarterly sales of $6.78 million, beating the analyst consensus estimate of $6.22 million by 9.02%. However, this is a 19.91% decrease over sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:06 pm

ATHA

Athira Pharma reported Q2 losses of $(0.78) per share, beating the analyst consensus estimate of $(0.79) by 1.27 percent. However, this represents a 20 percent increase in losses compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:06 pm

TISI

Team (NYSE:TISI) reported a decrease in sales this quarter, with $239.50 million compared to $251.26 million the same period last year, marking a 4.68 percent decrease.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:06 pm

SLRX

Salarius Pharmaceuticals reported Q2 losses of $(1.43) per share, missing the analyst consensus estimate of $(1.30) by 10 percent. However, this is a 36.44 percent improvement over losses of $(2.25) per share from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:05 pm

RKDA

Arcadia Biosciences reported Q2 earnings of $0.61 per share, beating the analyst consensus estimate of $(4.80) by 112.71%. However, the company's quarterly sales of $1.39 million missed the analyst consensus estimate of $1.82 million by 23.68%. This represents a 64.00% decrease over sales of $3.86 million the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 10, 2023 | 9:04 pm